Lipid Nanoparticle Radiotherapy With External Radionuclide Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The global shortage of radioactive materials produced by research reactors has necessitated the development of alternative methods for producing artificial radionuclides, and existing delivery systems for radioactive materials in radiotherapy face challenges in targeting specific cells effectively while minimizing side effects.
Innovation Solution
Biodegradable lipid nanoparticles are designed to encapsulate radioactive materials externally, utilizing linkers and nanoparticles to enhance targeting specificity and reduce side effects by incorporating target cell tropism, allowing for efficient delivery of alpha emitters like astatine to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If radioactive materials are produced by research reactors, then artificial radionuclides can be produced, but global supply becomes insufficient due to reactor shutdowns and shortages
Solution Approach 1:
The patent changes the production method parameter from nuclear reactor-based to accelerator-based production. This allows for more reliable and scalable production of radionuclides like astatine-211, addressing the supply shortages caused by research reactor limitations and shutdowns.
Solution Approach 2:
The patent replaces the nuclear reactor system with an accelerator-based system for radionuclide production. This substitution enables more flexible, reliable, and scalable production methods that are less susceptible to the shutdowns and supply constraints affecting traditional reactor-based approaches.
2Measurement precision
If conventional delivery systems are used for radioactive materials, then radiotherapy can be administered, but targeting specificity is insufficient and side effects increase
Solution Approach 1:
The patent introduces lipid nanoparticles as an intermediary carrier system between the radioactive material and target cells. These nanoparticles functionalized with specific ligands serve as mediators that enhance targeting specificity to cancer cells while minimizing exposure of normal cells, thereby reducing side effects.
Solution Approach 2:
The patent applies local quality by functionalizing lipid nanoparticles with specific ligands or antibodies that recognize target cell surfaces. This creates localized targeting capability where the nanoparticles accumulate preferentially at tumor sites, delivering radiation precisely where needed and sparing normal tissues.
3Productivity
If radioactive materials are delivered without specific targeting mechanisms, then administration is simplified, but delivery efficiency to target cells decreases
Solution Approach 1:
The patent creates a universal delivery platform using lipid nanoparticles that can be functionalized with various ligands or antibodies depending on the target cell type. This multi-functional system maintains high delivery efficiency across different cancer types while using a single nanoparticle platform, avoiding the need for entirely different delivery systems for each application.
Data Source
AI summary
According to one embodiment, a radiotherapy lipid nanoparticle includes a biodegradable lipid nanoparticle, and a radioactive material as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.